 PRINCETON, N.J., March 30, 2020 GLOBE NEWSWIRE -- Oyster Point Pharma, Inc. OYST, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced completion of enrollment in its pivotal Phase 3 ONSET-2 clinical trial of OC-01 nasal spray for the treatment of signs and symptoms of dry eye disease on March 14, 2020. In addition, Oyster Point Pharma provides a business update regarding the COVID-19 pandemic. The ONSET-2 trial is a multicenter, randomized, double-masked, placebo-controlled clinical trial to evaluate the safety and efficacy of OC-01 nasal spray for treating the signs and symptoms of dry eye disease. 